News

2020 AGM : The Word of the President

"Dear friends and colleagues,

We are still living under extraordinary pandemic conditions, but I hope nonetheless that you are facing the challenge with courage and optimism.

Why are we meeting today? Because our legal obligations as an association require us to maintain the mandatory points on the agenda. These include the 2019 annual accounts and the 2020 budget, as well as the validation of our newcomers."

Read more

Share on linkedin
Share on twitter
Share on facebook

From status quo to status go

Nuclear Medicine is based on the use of radioactivity for healthcare applications in diagnosis and therapy. Through the use of biomolecules that are labelled with radioisotopes, numerous metabolic, molecular and signalling pathways can be visualized and quantified. This information is used for diagnosis and personalized treatment planning.

The Innovation Working Group is updating and making publicly available their Pictorial Views about Nuclear Medicine. 

Following the publication of the updated "Cyclotrons for Medical Radionuclide Production", the latest update "From Status Quo to Status Go" is now available for download. 

Share on linkedin
Share on twitter
Share on facebook

COVID-19 and the global supply of Mo99

• Brussels, 11 May 2020

The Security of Supply Working Group (SoS WG) Emergency Response Team (ERT) held a teleconference on 11 May 2020 and received written updates from NMEu members regarding the impact of the COVID-19 pandemic on Mo-99 and other radioisotope production.

The improving situation reported in the last communication of 27 April continues and supply chain organizations maintain regular operations. Air transportation options for most geographic regions continue to improve. NTP reported that it is operating below capacity as a result of remaining logisitical challenges from South Africa.

Read the full statement

ERT_pictogram_500px
Share on linkedin
Share on twitter
Share on facebook

The European Parliament shows support to secure availability of radiopharmaceuticals

• Brussels, 22 April 2020

Nuclear Medicine Europe appreciates the action taken by the European Parliament with the European authorities concerned to highlight the difficulties encountered during the Covid-19 pandemic, with regard to the availability of radiopharmaceuticals.

Read the joint statement to Dr. Stella Kyriakides Commissioner for Health and Food Safety, European Commission, Dr. Thierry Breton Commissioner for Internal Market, European Commission, and Dr. Rafael Mariano Grossi, IAEA Director.

Share on linkedin
Share on twitter
Share on facebook

Short-term risk to security of supply of both bulk Mo-99 and Tc-99m generators

• Brussels, 20 April 2020

The Security of Supply Working Group (SoS WG) Emergency Response Team (ERT) held a teleconference on 20 April 2020 to discuss the impact of the COVID-19 pandemic on Mo-99 and other radioisotope production.

All organizations (research reactors, Mo-99 producers, Tc-99m generator manufacturers, ground transportation) continue to report regular operations. 

Read more

ERT_pictogram_500px
Share on linkedin
Share on twitter
Share on facebook

Update from the ERT

• Brussels, 15 April 2020

The Security of Supply Working Group (SoS WG) Emergency Response Team (ERT) held a teleconference on 15 April 2020 to discuss the impact of the COVID-19 pandemic on Mo-99 and other radioisotope production.

All organizations again reported that production operations continue normally within adjustments that have been taken against COVID-19, although production is being oriented to international flight availability. Radioisotope shipments from Europe have been more stable in recent weeks and continue via the reduced number of ongoing passenger flights.

Read more

ERT_pictogram_500px
Share on linkedin
Share on twitter
Share on facebook

Possible impact COVID-19 on the transport of medical radioisotopes

• Luxembourg, 01 April 2020

In this capacity, ESA has been in contact with the other co-chair – industry association of nuclear medicine - Nuclear Medicine Europe (NMEu), who expressed their concerns related to the impact of COVID-19 on the supply chain and in consequence on the availability of the most vital medical radioisotopes used in the nuclear medicine (namely Mo-99/Tc-99m).

Read more

Share on linkedin
Share on twitter
Share on facebook

Emergency Response Team

• Brussels, 24 March 2020

The Security of Supply Working Group (SoS WG) Emergency Response Team (ERT) held a teleconference on 23 March 2020 to discuss the continuing impact of the COVID-19 epidemic on Mo-99 and other isotope production. Despite increasing challenges, the Mo-99 supply chain has not yet experienced any significant disruptions, though all levels of the supply chain remain vigilant and continue to adopt business continuity measures to provide a reliable supply.

Read more

ERT_pictogram_500px
Share on linkedin
Share on twitter
Share on facebook

Crossing the Covid-19 period

• Brussels, 24 March 2020

In these turbulent times, we are aware of the safety measures to be taken at all levels in conformity to the recommendations of national and international public health authorities. We are particularly careful not to endanger the health and safety of our members and their representatives within NMEu.

Share on linkedin
Share on twitter
Share on facebook

AIPES and the Transport Expert Working Group on Channel 4 TV

Channel 4’s TV host Victoria Macdonald and her crew came last week to interview the members of the Transport Experts Working Group about the possible consequences of the Brexit on the transport of radiopharmaceuticals to the UK.

Full segment of the broadcast can be seen here :
https://www.youtube.com/watch?time_continue=1758

Cessation of Mo-99 Production Activities by NTP Radioisotopes Ltd.

• Brussels, 21 January 2019

ANSTO Press Release – OPAL reactor – Update

The AIPES Security of Supply working Group (SoS WG) composed of Mo-99 processors, research reactors, and generator manufacturers received an update from NTP Radioisotopes (South Africa) on 19 January concerning its Mo-99 and I-131 production activities.
NTP recently was authorized by the National Nuclear Regulator of South Africa to continue to perform routine Mo-99 production runs at around 40% of its capacity through the end of February 2019, which is the same level that has occurred since NTP returned to production in late November 2018. No Mo-99 or I-131 shortages have been experienced since NTP returned to service and none are anticipated in this upcoming period. NTP will update AIPES in late February regarding its Mo-99 and I-131 production activities.

Cessation of Mo-99 Production Activities by NTP Radioisotopes Ltd. (NTP)

• Brussels, 9 July 2018 

ANSTO Press Release – OPAL reactor - Update

The AIPES Emergency Response Team (ERT*) composed of Mo-99 processors, research reactors, and generator manufacturers had a telecon on Monday 9 July 2018 to receive an update from NTP Radioisotopes (South Africa) on the temporary interruption of its Mo-99 and I-131 production activities. NTP reported that following meetings and information and documentation submissions to National Nuclear Regulator (NNR), it continues to await NNR’s feedback and approval in response to its request to resume Mo-99 production operations.

Processors and Generators expressed that for the time being, there is no major problems in the production initially planned, and that all are trying to manage through the NTP production outage. Situation will have to be reconsidered in the coming days/weeks if there are no changes.

The ERT also discussed the article issued...

Read more

AIPES AGM 2018 dinner